What were Bristol Myers Squibb's first-quarter 2026 adjusted earnings and revenue, and how did they compare to Wall Street expectations?

Bristol Myers Squibb reported first-quarter adjusted earnings of $1.58 per share, surpassing the analysts' average expectation of $1.42 per share, and revenue of $11.49 billion, beating the expected $10.9 billion, according to LSEG data.

Which two product categories drove Bristol Myers Squibb's outperformance in Q1, and what were their key financial or market-share metrics?

Eliquis, the blood thinner co-marketed with Pfizer, generated $4.14 billion in quarterly sales — a 16% year-over-year increase — with new prescription share exceeding 75%; meanwhile, newer cancer medicines including Breyanzi and Camzyos contributed to a 12% growth in the company’s growth portfolio, which reached $6.23 billion and accounted for over half of total revenue.

Bristol Myers beats quarterly profit estimates on blood thinner, cancer drug sales

Apr 30, 2026

Bristol Myers Squibb exceeded Q1 profit expectations on strong Eliquis and cancer drug sales, boosting shares 4%. It reaffirmed its 2026 outlook and intends to leverage AI to accelerate drug discovery alongside ongoing cost-cutting initiatives.

reuters

2026-04-30

Bristol Myers beats quarterly profit estimates on blood thinner, cancer drug sales

2026-05-15

BMS Is Latest Big Pharma Firm to Partner with China’s Hengrui

2026-05-20

Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery

2026-07-30

Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results

Bristol Myers beats quarterly profit estimates on blood thinner, cancer drug sales

FAQ